167 related articles for article (PubMed ID: 20370683)
1. Inhibition of c-Met with the specific small molecule tyrosine kinase inhibitor SU11274 decreases growth and metastasis formation of experimental human melanoma.
Kenessey I; Keszthelyi M; Krámer Z; Berta J; Adám A; Dobos J; Mildner M; Flachner B; Cseh S; Barna G; Szokol B; Orfi L; Kéri G; Döme B; Klepetko W; Tímár J; Tóvári J
Curr Cancer Drug Targets; 2010 May; 10(3):332-42. PubMed ID: 20370683
[TBL] [Abstract][Full Text] [Related]
2. c-Met is a potentially new therapeutic target for treatment of human melanoma.
Puri N; Ahmed S; Janamanchi V; Tretiakova M; Zumba O; Krausz T; Jagadeeswaran R; Salgia R
Clin Cancer Res; 2007 Apr; 13(7):2246-53. PubMed ID: 17404109
[TBL] [Abstract][Full Text] [Related]
3. PTEN reconstitution alters glioma responses to c-Met pathway inhibition.
Goodwin CR; Lal B; Ho S; Woodard CL; Zhou X; Taeger A; Xia S; Laterra J
Anticancer Drugs; 2011 Oct; 22(9):905-12. PubMed ID: 21654317
[TBL] [Abstract][Full Text] [Related]
4. Tyrosine kinase inhibitor SU11274 increased tumorigenicity and enriched for melanoma-initiating cells by bioenergetic modulation.
Kucerova L; Demkova L; Skolekova S; Bohovic R; Matuskova M
BMC Cancer; 2016 May; 16():308. PubMed ID: 27175734
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of phosphorylated c-Met in rhabdomyosarcoma cell lines by a small molecule inhibitor SU11274.
Hou J; Dong J; Sun L; Geng L; Wang J; Zheng J; Li Y; Bridge J; Hinrichs SH; Ding SJ
J Transl Med; 2011 May; 9():64. PubMed ID: 21575221
[TBL] [Abstract][Full Text] [Related]
6. Effect of c-Met inhibitor SU11274 on hepatocellular carcinoma cell growth.
Inagaki Y; Qi F; Gao J; Qu X; Hasegawa K; Sugawara Y; Tang W; Kokudo N
Biosci Trends; 2011; 5(2):52-6. PubMed ID: 21572247
[TBL] [Abstract][Full Text] [Related]
7. [Study of motogenic signal in human melanoma cells].
Kenessey I
Magy Onkol; 2011 Mar; 55(1):55-8. PubMed ID: 21617791
[TBL] [Abstract][Full Text] [Related]
8. The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants.
Berthou S; Aebersold DM; Schmidt LS; Stroka D; Heigl C; Streit B; Stalder D; Gruber G; Liang C; Howlett AR; Candinas D; Greiner RH; Lipson KE; Zimmer Y
Oncogene; 2004 Jul; 23(31):5387-93. PubMed ID: 15064724
[TBL] [Abstract][Full Text] [Related]
9. Effect of a c-Met-specific, ATP-competitive small-molecule inhibitor SU11274 on human ovarian carcinoma cell growth, motility, and invasion.
Koon EC; Ma PC; Salgia R; Welch WR; Christensen JG; Berkowitz RS; Mok SC
Int J Gynecol Cancer; 2008; 18(5):976-84. PubMed ID: 18021219
[TBL] [Abstract][Full Text] [Related]
10. The green tea polyphenol EGCG potentiates the antiproliferative activity of c-Met and epidermal growth factor receptor inhibitors in non-small cell lung cancer cells.
Milligan SA; Burke P; Coleman DT; Bigelow RL; Steffan JJ; Carroll JL; Williams BJ; Cardelli JA
Clin Cancer Res; 2009 Aug; 15(15):4885-94. PubMed ID: 19638461
[TBL] [Abstract][Full Text] [Related]
11. A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo.
Christensen JG; Schreck R; Burrows J; Kuruganti P; Chan E; Le P; Chen J; Wang X; Ruslim L; Blake R; Lipson KE; Ramphal J; Do S; Cui JJ; Cherrington JM; Mendel DB
Cancer Res; 2003 Nov; 63(21):7345-55. PubMed ID: 14612533
[TBL] [Abstract][Full Text] [Related]
12. A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase.
Sattler M; Pride YB; Ma P; Gramlich JL; Chu SC; Quinnan LA; Shirazian S; Liang C; Podar K; Christensen JG; Salgia R
Cancer Res; 2003 Sep; 63(17):5462-9. PubMed ID: 14500382
[TBL] [Abstract][Full Text] [Related]
13. Identification of the receptor tyrosine kinase c-Met and its ligand, hepatocyte growth factor, as therapeutic targets in clear cell sarcoma.
Davis IJ; McFadden AW; Zhang Y; Coxon A; Burgess TL; Wagner AJ; Fisher DE
Cancer Res; 2010 Jan; 70(2):639-45. PubMed ID: 20068147
[TBL] [Abstract][Full Text] [Related]
14. Effect of c-Met inhibitor SU11274 on human colon cancer cell growth.
Gao SH; Liu C; Wei J; Feng Y
Chin Med J (Engl); 2013 Jul; 126(14):2705-9. PubMed ID: 23876900
[TBL] [Abstract][Full Text] [Related]
15. Study of critical role of c-Met and its inhibitor SU11274 in colorectal carcinoma.
Gao W; Bing X; Li M; Yang Z; Li Y; Chen H
Med Oncol; 2013 Jun; 30(2):546. PubMed ID: 23536000
[TBL] [Abstract][Full Text] [Related]
16. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer.
Ma PC; Jagadeeswaran R; Jagadeesh S; Tretiakova MS; Nallasura V; Fox EA; Hansen M; Schaefer E; Naoki K; Lader A; Richards W; Sugarbaker D; Husain AN; Christensen JG; Salgia R
Cancer Res; 2005 Feb; 65(4):1479-88. PubMed ID: 15735036
[TBL] [Abstract][Full Text] [Related]
17. Co-expression of hepatocyte growth factor and c-Met predicts peritoneal dissemination established by autocrine hepatocyte growth factor/c-Met signaling in gastric cancer.
Toiyama Y; Yasuda H; Saigusa S; Matushita K; Fujikawa H; Tanaka K; Mohri Y; Inoue Y; Goel A; Kusunoki M
Int J Cancer; 2012 Jun; 130(12):2912-21. PubMed ID: 21796631
[TBL] [Abstract][Full Text] [Related]
18. γ-Tocotrienol inhibits HGF-dependent mitogenesis and Met activation in highly malignant mammary tumour cells.
Ayoub NM; Bachawal SV; Sylvester PW
Cell Prolif; 2011 Dec; 44(6):516-26. PubMed ID: 21973114
[TBL] [Abstract][Full Text] [Related]
19. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma.
Seiwert TY; Jagadeeswaran R; Faoro L; Janamanchi V; Nallasura V; El Dinali M; Yala S; Kanteti R; Cohen EE; Lingen MW; Martin L; Krishnaswamy S; Klein-Szanto A; Christensen JG; Vokes EE; Salgia R
Cancer Res; 2009 Apr; 69(7):3021-31. PubMed ID: 19318576
[TBL] [Abstract][Full Text] [Related]
20. Novel targeting of phospho-cMET overcomes drug resistance and induces antitumor activity in multiple myeloma.
Moschetta M; Basile A; Ferrucci A; Frassanito MA; Rao L; Ria R; Solimando AG; Giuliani N; Boccarelli A; Fumarola F; Coluccia M; Rossini B; Ruggieri S; Nico B; Maiorano E; Ribatti D; Roccaro AM; Vacca A
Clin Cancer Res; 2013 Aug; 19(16):4371-82. PubMed ID: 23804425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
